文献速递前列腺癌

局部性前列腺癌质量指标依从性的国际差异

International Variations in Adherence to Quality Metrics for Locoregional Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2024-06-08

该研究基于10国Movember TrueNTH全球登记(n=62688,2013—2022)的局部性前列腺癌患者,评估四项质量指标依从性的地区差异。结果显示各指标依从率地区间差异显著,主动监测率从澳大利亚/新西兰85%至中欧14%,不利风险12个月内根治治疗率中欧98%至意大利70%,有利风险未行影像比例美国94%至意大利30%,不利风险影像率香港8%至美国39%(均χ²p<0.0125)。

要点

  • 低危前列腺癌主动监测率从澳大利亚/新西兰85%至中欧14%,地区差异显著。
  • 不利风险12个月内根治治疗率中欧98%至意大利70%,地区间差异显著。
  • 有利风险未行影像比例美国94%至意大利30%,不利风险影像率香港8%至美国39%。

核心结论

  • 在比较局部性前列腺癌质量指标依从性的国际研究中,发现地区差异,可能源于文化态度和医疗体系结构差异;这些基准值提示可通过干预提高循证指南依从性。

研究设计与样本

  • 研究队列为10国Movember TrueNTH全球登记中2013—2022年诊断的局部性前列腺癌患者(n=62688)。
  • 评估四项质量指标:低危主动监测、不利风险12个月内根治治疗、有利风险无分期影像、不利风险有分期影像。
  • χ²分析合并各区域最近三年数据并校正多重检验(p=0.05÷4=0.0125),另行多变量逻辑回归和时间趋势分析。

主要发现

  • 低危主动监测率从澳大利亚/新西兰85%(vs 美国:aOR 1.042,95%CI 0.740-1.520)至中欧14%(aOR 0.028,95%CI 0.022-0.036)。
  • 不利风险12个月内治疗率中欧最高98%(aOR 2.885,95%CI 1.260-6.603),意大利70%(aOR 0.031,95%CI 0.014-0.072)。
  • 有利风险未行影像比例美国94%至意大利30%(aOR 0.004,95%CI 0.002-0.008),不利风险影像率香港8%(aOR 65.222,95%CI 43.676-97.398)至美国39%(所有χ²p<0.0125)。
  • 区域时间趋势亦存在差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Adherence to guideline recommendations can improve the quality of care for patients with prostate cancer (PCa). Our aim was to assess adherence to guidelines for locoregional PCa by international region. METHODS: The study cohort comprised patients diagnosed with locoregional PCa in the 10-country Movember TrueNTH Global Registry (n = 62 688; 2013-2022). We assessed adherence to four quality metrics: (1) active surveillance for low-risk PCa; (2) definitive treatment within 12 mo of diagnosis for unfavorable-risk PCa; (3) no staging imaging for favorable-risk PCa; and (4) staging imaging for unfavorable-risk PCa. For χ2 analyses, we combined the three most recent years of data entered by region for each outcome, with adjustment for multiple tests (p = 0.05 ÷ 4 = 0.0125). We also conducted multivariable logistic regression and temporal analyses. KEY FINDINGS AND LIMITATIONS: Active surveillance rates for low-risk PCa ranged from 85% in Australia/New Zealand (vs USA: adjusted odds ratio [aOR] 1.042, 95% confidence interval [CI] 0.740-1.520) to 14% in Central Europe (aOR 0.028, 95% CI 0.022-0.036). For patients with unfavorable-risk disease, the highest uptake rate for treatment within 12 mo of diagnosis was in Central Europe (98%; aOR 2.885, 95% CI 1.260-6.603), compared to 70% in Italy (aOR 0.031, 95%CI 0.014-0.072). The proportion of patients with favorable-risk disease who did not undergo imaging ranged from 94% in the USA to 30% in Italy (aOR 0.004, 95% CI 0.002-0.008), while the rate of imaging for unfavorable-risk PCa ranged from 8% in Hong Kong (aOR 65.222, 95% CI 43.676-97.398) to 39% in the USA (all χ2p < 0.0125). Regional temporal trends also varied. CONCLUSIONS AND CLINICAL IMPLICATIONS: In this international study comparing adherence to quality care metrics for the quality of care for locoregional PCa, we identified regional variance, possibly because of regional differences in cultural attitudes and health care structures. These benchmarks highlight opportunities for interventions to improve adherence to evidence-based guidelines. PATIENT SUMMARY: Our study shows that adherence to recommended management goals for patients with prostate cancer varies greatly by global region.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Weiner AB, Nguyen AV, Kishan AU, et al. International Variations in Adherence to Quality Metrics for Locoregional Prostate Cancer. Eur Urol Oncol. 2024. PMID: 38851994. doi:10.1016/j.euo.2024.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。